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Abstract
Background: Although the occurrence of acute myeloid leukemia (AML) after chemotherapy for multiple myeloma
(MM) is common in clinical settings, the simultaneous occurrence of these malignancies in patients without
previous exposure to chemotherapy is a rare event. Etiology, disease management, and clinical treatment remain
unclear for this particular occurrence. To the best of our knowledge, this study is the first to report a case of
simultaneous presentation of AML and MM after exposure to ultraviolet irradiation.
Case presentation: We reported the case of a 73-year-old man (Han Chinese ethnicity) without previous medical
history of AML and MM. The morphology and immunology of bone marrow cells confirmed the co-existence of
AML and MM. Fluorescent in situ hybridization analysis of immunomagnetically separated abnormal plasma cells
showed abnormal expression of the amplified RB-1, TP53, and CDKN2C (1p32). Cytogenetic analysis demonstrated
Y chromosome deletion.
After the patient was administered with bortezomib combined with cytarabine + aclarubicin + granulocyte colony-
stimulating factor (CAG regimen), and evident curative effects were observed. The patient achieved and maintained
complete remission for more than 6 months. Prior to the disease occurrence, the patient had received ultraviolet
irradiation for 1 year and was detected with aberrant gene expression of RB-1, TP53, and CDKN2C (1p32).
Nevertheless, the correlation of this phenomenon with the etiology of concurrent AML with MM remains unclear.
Conclusion: This study discussed the case of a patient diagnosed with AML concurrent with MM, who has no
previous exposure to chemotherapy. This patient was successfully treated by bortezomib combined with CAG
regimen. This study provides a basis for clinical treatment guidance for this specific group of patients and for
confirmation of the disease etiology.
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Background
The association of acute myeloid leukemia (AML) with
multiple myeloma (MM) is described as a complication
of chemotherapy but may also occur in the absence of
this treatment. The simultaneous occurrence of AML
and MM in a patient without previous exposure to
chemotherapy is a rare event. Only nine cases of this
phenomenon had been reported in the literature until
2003 according to Luca and Almanaseer [1]. These cases
of AML concurrent with MM reported from 1989 to
2014 were retrieved from the PUBMED database [2–10].
Three of these cases presented simultaneous occur-
rence of AML and MM at first diagnosis, even without
prior exposure to chemotherapy [1, 3, 6]. Herein we
reported a case of simultaneous occurrence of AML and
MM in a patient without previous exposure to chemother-
apy. This study was approved by the Ethics Committee of
the Qilu Hospital of Shandong University. An informed
consent form was signed by the patient.
A 73-year-old man without previous medical history
bought an ultraviolet irradiation apparatus and received
ultraviolet irradiation for 1–2 h daily for 1 year to main-
tain health and enhance immunity,because he believed
that this method can promote local blood circulation, thus
benefiting his physical health. (This method is atypical in
China.) The patient did not smoke and had no family
history of cancer. He had developed progressive fatigue
and dizziness for 6 months and presented needle-like sub-
cutaneous hemorrhage on both lower limbs for 1 week.
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Examination results showed pallor, needle-like subcutane-
ous hemorrhage, petechiae, sore sternum, and splenomeg-
aly of 1.5 cm under the ribs. The patient had a white
blood cell count of 2.1 × 109 per liter, hemoglobin level of
57 g/L, platelet count of 23 × 109 per liter, and erythrocyte
sedimentation rate of 156 mm/h. We carried out the de-
tection of serum M-protein by electrophoresis test and
the result confirmed the presence of monoclonal im-
munoglobulin M. Serum immunofixation test revealed a
monoclonal IgA/λ band. Quantitative immunoglobulin
analysis showed the following contents: IgG 9.22 g/L (NV
7.0–16 g/L); IgA, 14.4 g/L (NV 0.7–4 g/L); IgM 0.33 g/L
(NV 0.4–2.3 g/L); IgE1 124.0 (NV 0–100 g/L);β2-MG,
3.09 mg/L (NV 0.7–1.8 mg/L); λ (lambda) light chain,
4.62 g/L (NV 0.9–2.1 g/L); κ (Kappa) light chain, 2.14 g/L
(NV 1.7–3.1 g/L), with serum free κ/λ ratio, 0.46 (NV
1.35–2.65). The smear of aspirated bone marrow (BM)
cells revealed 45 % myeloblast cells (non-erythroid cells,
NEC) and about 17 % highly atypical plasma cells (NEC),
as shown in Fig. 1a and b, respectively. X-ray examination
revealed no abnormal changes in the patient’s bone. No
other signs were observed on the X-ray results.
The results of BM trephine biopsy showed increased
hyperplasia activity (70 %), widely distributed naive cells,
large cell body, abundant cytoplasm, and several irregu-
lar nuclei with prominent nucleoli. The percentage of
plasma cell increased, and these cells featured special-
shaped scattered or clustered distribution with positively
stained reticular fibers (Fig. 1c).
Bone marrow mononuclear (BMM) cells of the patient
(one sample) included fluorochrome-conjugated anti-
bodies to the following antigens CD138, CD38 with λ
light-chain restriction; another sample of the BMM cells
included fluorochrome-conjugated antibodies to the
following antigens of CD117, CD33, CD34, HLA-DR,
CD15, CD56, CD7, CD17, and MPO. The Cell popula-
tion classification of some specific antigen with “ + ” and
not “-” were detected by using flow cytometry (FACSAr-
iaII, USA). The results of flow cytometric immunophe-
notyping showed about 13 % atypical plasma cells
positive for CD138 and CD38 with λ light-chain restric-
tion, which indicated as multiple myeloma cells (Fig. 1d).
Another group cells expressed CD117, CD34, CD33,
HLA-DR, CD15, CD56, CD7, CD17 and MPO occupied
about 60 % and characterized as malignant myeloid cells
(Fig. 1e).
Fluorescent in-situ hybridization (FISH) analysis of
immunomagnetically separated abnormal plasma cells
showed aberrant expression of the amplified RB-1, TP53,
and CDKN2C (1p32) (Fig. 1f). (note: In the present study
the hybridized probes of FISH test included RB-1,TP53,
Bcr/abL, PML/RARA, AML1/ETO, MLL, FGFR1, CBFB,
TET/AML, Bcl-2, MYC, CCND1/IgH; of those negative
bio-markers did not listed.) The immune markers of bone
marrow myeloid and plasma cells or myeloid cells were
determined by flow cytometry. The results showed the
positive expression of CD138 in bone marrow plasma
cells, whereas CD38, CD117, CD33, CD34, LHA-DR,
CD15, CD56, CD7, CD17, and MPO were all positively
expressed in bone marrow myeloid cells.
As shown in Fig. 2, conventional cytogenetic analysis
demonstrated Y chromosome deletion.
The patient was diagnosed with concurrent AML and
MM according to the diagnostic criteria of MM on the
international guidelines 2014NCCN (National Compre-
hensive Cancer Network). He was initially treated with
1.3 mg/m2 bortezomib for days 1, 4, 8, and 11 with
1.3 mg/m2 bortezomib, which was combined with the
CAG regimen: 10 mg of Acla iv drip for d1–8, 15 mg of
Ara-C im q12h for d1–14, and 300 μg of G-CSF ih qd
on d1-14. After 2 weeks, bone marrow level was normal-
ized with lower than 5 % residual myeloblast and atyp-
ical plasma cells. The patient was treated with the same
regimen for three additional cycles and remained in
complete stable remission. After treatment, the patient’s
dizziness, nausea, fatigue, pallor, needle-like subcutane-
ous hemorrhage, petechiae, and sore sternum symptoms
disappeared; the enlarged spleen of the patient was
reduced and did not touch the lower ribs. Laboratory
examination showed that Hb was 98 g/L. Quantitative
immunoglobulin analysis presented the following
contents: IgG, 9.67 g/L (NV 7.0–16 g/L); IgA, 1.35 g/L
(NV 0.7–4 g/L); IgM, 0.51 g/L (NV 0.4–2.3 g/L); IgE1, 27.2
(NV 0–100 g/L); β2-MG, 3.51 mg/L (NV 0.7–1.8 mg/L); λ
(lambda) light chain, 1.48 g/L (NV 0.9–2.1 g/L); κ (kappa)
light chain, 2.22 g/L (NV 1.7–3.1 g/L); and serum-free κ/λ
ratio, 1.50 (NV 1.35–2.65). Compared with the results of
quantitative immunoglobulin analysis in the diagnosis
upon admission, the patient’s IgA and λ levels decreased by
90.62 % and 67.96 %, respectively, with a normal serum-
free κ/λ ratio. Immature cells were not found in peripheral
blood smear, and the bone marrow normalized with <5 %
residual myeloblasts and atypical plasma cells. Cerebro-
spinal fluid examination did not show any abnormal find-
ing. These results indicated that the patient underwent
remission because of the curative effects of both AML and
MM. The patient achieved and maintained complete remis-
sion for more than 6 months on the last follow-up of March,
20, 2015 (a flow diagram figure shows in Additional file 1).
Discussion
Case presentation
Although some reviewers postulated that secondary
AML occurs during complete remission of MM after
chemotherapy, other scholars hypothesized that mye-
loma cells can stimulate bone marrow during cell prolif-
eration, this phenomenon may result in subsequent
development of a second hematological malignancy,
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particularly in cases with Rb-1 deletion [5]. Reports
showed that the underlying monoclonal gammopathy of
undetermined significance (MGUS) progresses to MM,
resulting in the co-existence of MGUS and AML, par-
ticularly in elderly patients [9]. The simultaneous devel-
opment of AML and MM in a patient without previous
exposure to chemotherapy is a rare event. The possibility
that these two malignancies may originate from com-
mon stem cells has not been supported with evidence.
Malhotra et al. [11–13] reported 15 cases diagnosed with
both Philadelphia chromosome-negative myeloprolifera-
tive neoplasms (MPNs) and MGUS or multiple myeloma
(MM) at their institute over a period of 5 years (January
2008 to December 2012). Eleven patients with MGUS
and two patients with MM had received prior radiation
treatment or chemotherapy and then developed MPNs.
The two other patients with MM who did not received
any cytotoxic treatment developed myelofibrosis. MGUS
(Monoclonal gammapathies) denotes the presence of a
monoclonal protein without manifesting MM features or
other related malignant plasma-cell disorders, such as
Waldenstrom macroglobulinemia, primary amyloidosis,
B-cell lymphoma, and chronic lymphocytic leukemia [14].
The vast majority of MGUS patients did not present any
symptoms. Clinical observations regarding the develop-
ment from MGUS to MM indicated the absence of symp-
toms such as anemia, bone destruction, hypercalcemia,
and renal function damage; only the serum M protein and
the number of bone marrow plasma cells showed changes
[15]. In the current study, we report a patient who under-
went regular physical examination annually for 5 years
and did not manifest any clinical symptoms, such as
anemia, bone destruction, hypercalcemia, renal function
damage, and abnormal immunoglobulin items, through
Fig. 2 Conventional cytogenetic analysis demonstrated 45 ×, −y [6]
(See figure on previous page.)
Fig. 1 Bone marrow (BM) aspirate smear showed primitive and immature mononuclear cells (a: original magnification × 100 under oil) and abnormal
plasma cell morphology (b: original magnification × 100 under oil). BM trephine biopsy showed increased hyperplasia activity (70 %), widely distributed
naive cells, large cell body, abundant cytoplasm, and several irregular nuclei with prominent nucleoli. The percentage of plasma cells increased, and
the cells featured special-shaped scattered or clustered distribution with positively stained reticular fibers (c: original magnification × 100 under oil).
d: Flow cytometric immunophenotyping of abnormal plasma cells showed positive CD138, CD38, CD56 and λ expression, and negative CD19 and
CD45 expression. e: The phenotypic characteristics of malignant myleoid cells showed strong positive CD38 expression, positive CD117, CD34, CD33,
HLA-DR, CD56, CD13, and MPO expression, and negative CD5, CD11, CD64, CD20, and CD70 expression. f: The gene expression of RB-1, IgH, TP53, and
CDKN2C/CKS1B as indicated by the results of FISN analysis on immunomagnetically separated abnormal plasma cells. Note: A-1, B-1, C-1, and D-1 for
normal bone marrow cells; A-2, B-2, C-2, and D-2 for the patient’s bone marrow cells. Testing of RB-1 (13q14) by using Vysis and monochrome-labeled
probe showed normal 2R signal (A-1) and positive 1R signal characteristics (A-2) (fusion signal showing red color). Testing of IgH (14q32) by using Vysis
and dual-color separately labeled probe (signal: green for 5′ IgH and red for 3′ IgH) showed fusion signal with yellow color or green–red overlying
color, which represented normal expression of IgH in B-1 and B-2. Testing of TP53 (17p13) by using Vysis and monochrome-labeled probe showed nor-
mal 2R signal (C-1) and positive 1R signal characteristics (C-2) (fusion signal showing red color). Testing of CDKN2C (1p32)/CKS1B (1q21) by using Vysis
and dual-color separately labeled CKS1B/CDKN2C probe (signal: green for CDKN2C and red for CKS1B) showed normal 2R2G signal and characteristics in
D-1 and positive signal for 3R2G 1q21 amplification and 2R1G deletion of 1p32 in D-2
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routine clinical laboratory examinations. The present case
was demonstrated myeloid cell malignancy and atypical
plasma cells on cytology based on the immune markers of
bone marrow myeloid cells and bone marrow plasma cells
were determined by flow cytometry. The results showed
that the CD138 positive expression of bone marrow
plasma cells,and the CD38 strong expresion, the CD117,
CD33, CD34 and LHA-DR positive expression, and
CD15,CD56, CD17 and MPO part or weak positive ex-
pression of bone marrow myeloid cells and FISH analyses
of magnetically separated plasma cells. The presence of
the M protein in immune fixation electrophoresis sup-
ported the diagnosis of concurrent AML and MM without
history of chemotherapy except ultraviolet irradiation.
The mechanism of the simultaneous occurrence of
AML and MM without exposure to chemotherapy
remains unclear. The deletion of RB-1, TP53, and lP32
was associated with the simultaneous occurrence of
AML and MM. We speculate that multiple gene muta-
tion or some susceptible genes may be involved in the
simultaneous occurrence of both malignancies. Never-
theless, the mechanism underlying the simultaneous oc-
currence of AML and MM must be further investigated.
Studies have reported that disease management in
patients who developed MM focuses on myeloma treat-
ment. Anti-cancer agents, such as thalidomide, lenalido-
mide, and pomalidomide, demonstrated evident activity in
MPN and MM and should be considered in the treatment
regimen [16].
The concurrent prognosis of AML and MM remains
very poor, and a standard treatment regimen has not
been established. Murukutla et al. [10] summarized the
therapy experiences of patients in prior reports, which
included the use of drugs, such as bortezomib, tipifarnib,
cyclophosphamide, vincristine, cytarabine, idarubicin,
melphalan, and prednisone. Recently, Kim et al. [8]
reported a 51-year-old man who had no past medical
history but presented with simultaneous diagnosis of
myeloma and AML, which were successfully treated
with allogeneic stem cell transplantation. However, these
therapy experiences are insufficient to construct a model
protocol. The combination of bortezomib with CAG
exhibits evident curative effects on elderly patients who
are not suitable for allogeneic stem cell transplantation.
In the present case, the patient achieved and maintained
remission for more than 6 months. This finding may
benefit the selection of optimum treatment options for
this specific group of patients.
UV radiation is a complete carcinogen, especially for
long-term management of children and young adults
and in combination with topical or systemic immuno-
suppressants [17]. We suspect the patient’s malignancy
may be related to exposure to the UV radiation, but that
no data to proof this hypothesis can be given.
The genetic and molecular biomarkers of a case with
simultaneous AML and MM have made considerable
progress with the technological developments of flow cy-
tometry and FISH. Before 2003, all case reports of simul-
taneous presentation of AML and MM performed a type
of serum immunofixation test that revealed the types
of paraproteins in patients, including IgA, IgA/k, IgG,
IgG/k, and IgG/λ; however, few cases conducted the
chromosome type test, and the results displayed 46XY
and hypodiploidy, as well as chromosomal abnormalities
[3, 10]. Luca DC and Almanaseer IY (2003) [1] performed
an immunohistochemical test (flow cytometric analysis),
which demonstrated myeloblasts with positive expression
of Cd14, CD33, and HLA-DR, and a negative expression
of CD45 for plasma cells; cytogenetic test showed that the
karyotype was monosomy 13. Kim et al. [8] reported a
case of simultaneous presentation of AML and MM with
k-type paraprotein; immunohistochemical test of the case
revealed plasma cells to be positive for CD138 with kappa
light chain restriction and myeloblasts to be positive
for CD34 and CD117; flow cytometric test confirmed
the presence of two distinct neoplastic populations of
plasma cells and myeloblasts; fluorescence in situ
hybridization (FISH) test revealed a complex chromo-
somal pattern, with +5, +7, +8, +8q22, +11q23, −13q14,
−16q22, +17q13.1, +20q12, and +21q22, and immuno-
globulin heavy chain (IgH) rearrangement. The present
study showed that the new biomarkers included the ab-
normal expression levels of the amplified RB-1, TP53, and
CDKN2C (1p32) for plasma cells by FISH, as well as the
positive or partial expression of CD33, CD15, CD56, CD7,
CD17, and MPO for myeloblasts via flow cytometric test.
In the present study, the hybridized probes of FISH
test included RB-1, TP53, Bcr/abL, PML/RARA,
AML1/ETO, MLL, FGFR1, CBFB, TET/AML, Bcl-2,
MYC, and CCND1/JgH. However, gene mutation was
not detected for the negative biomarkers by FISH
analysis. Some recent reports showed that FLT3 ITD,
NPM1, or CEBPA mutation is associated with AML
[18–20]. Testing the gene mutation for the negative
biomarkers of FISH analysis is the most feasible idea.
However, the limitation of this study was the failure
to perform the gene mutation test for the negative
molecules of FISH test, such as FLT3, ITD, NPM1,
and CEBPA.
Conclusion
A patient without previous exposure to chemotherapy
was diagnosed with concurrent AML with MM and
successfully treated using bortezomib combined with
the CAG regimen. This treatment strategy could be a
reasonable option for future cases with similar diag-
nosis. The findings presented in this case report may
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particularly benefit patients presented abnormal ex-
pression of the amplified RB-1, TP53, and CDKN2C
(1p32) and the confirmation of the disease etiology
(a cheklist item description shows in Additional file 2).
Consent section
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the editor of this journal.
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